25 Jul How to launch a drug in Europe
There are many obstacles to the first launch of a drug in the European markets, even more for non-European biopharmaceutical companies. One needs to consider the nature of the product and patient demand, establish a brand, clearly define a tailored go-to-market strategy, and build relationships with local partners that can help navigate the regulatory landscape. Then executing smoothly (while also not forgetting that Europe is multicultural).
To get some first-hand insights on this, we have set-up a seminar with KPMG, a partner of BaseLaunch, during which they will take you through the key takeaways of their recent publication “Your first European launch: a prescription for growth”. This builds on their profound experience of having helped various biotech’s in setting-up their European operations. In addition, we are thrilled to also have Giacomo di Nepi, CEO of Polyphor, joining and sharing his insights on how he successfully built up the European operations of Intermune from the start. A company, which was ultimately sold to Roche for over 8 billion dollars.
When: 20.08.2019, 16:15 to 17:30
Where: Switzerland Innovation Park Basel Area, Room Vision, Gewerbestrasse 24, 4123 Allschwil
Participation to the event is free of charge; however, your registration by 18th August 2019 is kindly required.
Leonildo Delgado, BaseLaunch
16:20 Intro: KPMG
Martin Rohrbach, Sector Head Life Sciences KPMG Switzerland
16:30 Your first European launch: a prescription for growth
Nicolas Gimenez-Stamminger & Hans Mies, KPMG Switzerland
17:00 Building out European operations for Intermune from the start
Giacomo di Nepi, CEO Polyphor
17:30 Q&A and apero